Sharon Townson - Jun 23, 2021 Form 3 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role
Chief Technology Officer
Signature
/s/ Ajim Tamboli, Attorney-in-Fact
Stock symbol
GLUE
Transactions as of
Jun 23, 2021
Transactions value $
$0
Form type
3
Date filed
6/23/2021, 08:32 PM
Next filing
Mar 2, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GLUE Stock Option (Right to Buy) Jun 23, 2021 Common Stock 75K $1.13 Direct F1
holding GLUE Stock Option (Right to Buy) Jun 23, 2021 Common Stock 215K $6.14 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on July 20, 2021, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F2 25% of this option shall vest and become exercisable on April 9, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.

Remarks:

Exhibit 24 - Power of Attorney